Stocks Health care TGTX
NASDAQ · Health careTG Therapeutics, Inc. (TGTX)
TG Therapeutics, Inc. brought in $897.8M of revenue over the twelve months to September 30, 2026, up 68.8% from a year earlier. Net income was $106.1M, a net margin of 11.8%. In fiscal 2025 capital spending exceeded operating cash flow by $25M. At September 30, 2026 it held $429.4M in cash against $745.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about TG Therapeutics, Inc.
- Net worth
- TG Therapeutics, Inc. has a market value (market cap) of $9.7B at the latest share price, and shareholders' equity of $572.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $616.3M (+87.3% year on year), with net income of $447.2M. Over the 12 months to September 30, 2026: revenue $897.8M, net income $106.1M.
- Cash flow
- In fiscal 2025 operations used $24.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- TG Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What TG Therapeutics, Inc. does
TG Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker TGTX.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $616.3M | $447.2M | $2.77 | -$25M |
| 2024 | $329M | $23.4M | $0.15 | -$40.6M |
| 2023 | $233.7M | $12.7M | $0.09 | -$31.4M |
| 2022 | $2.8M | -$223.8M | -$1.65 | -$176.2M |
| 2021 | $6.7M | -$348.1M | -$2.97 | -$296M |
| 2020 | $152K | -$279.4M | -$2.73 | -$214.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where TGTX ranks in Health care
Latest SEC filings
What TG Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 61% to $259.9M versus the same quarter last year; diluted EPS $0.35 versus $2.43.
- November 9, 2026
- October 27, 2026Passive stake changed SCHEDULE 13G/A
- August 5, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 70% to $240.3M versus the same quarter last year; diluted EPS $0.05 versus $0.17.
- August 3, 2026
- June 12, 2026
- June 3, 2026Other event 8-K
- May 27, 2026Other event 8-K
- May 6, 2026Quarterly report 10-Q · period to March 31, 2026Revenue rose 70% to $204.9M versus the same quarter last year; diluted EPS $0.12 versus $0.03.
- May 6, 2026
Insider trades
What the people running TG Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $274.8K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 10, 2026 | Charney Laurence NDirector | Sold | 5,000 | $274.8K |
| August 7, 2026 | Charney Laurence NDirector | Gave as a gift | 500 | - |
| August 7, 2026 | Charney Laurence NDirector | Gave as a gift | 450 | - |
| August 6, 2026 | Charney Laurence NDirector | Gave as a gift | 5,100 | - |
| January 29, 2026 | Charney Laurence NDirector | Gave as a gift | 13,197 | - |
| January 28, 2026 | Charney Laurence NDirector | Gave as a gift | 30,000 | - |
| January 8, 2026 | Power Sean ACFO | Received as pay | 90,000 | - |
| January 8, 2026 | Weiss Michael SCEO, Director | Received as pay | 622,000 | - |
Who owns TGTX
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| BlackRock, Inc.13G, passive | 13.8% | October 27, 2026 |
| Vanguard Portfolio Management13G, passive | 5.26% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 428 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 22,050,045 | -202,885 |
| Vanguard Portfolio Management LLC | 7,963,266 | -310,713 |
| State Street Corp | 7,786,471 | -863,295 |
| Vanguard Capital Management LLC | 6,149,403 | -453,855 |
| Geode Capital Management, LLC | 3,642,216 | +142,300 |
| D. E. Shaw & Co., Inc. | 3,400,808 | +2,810,761 |
| Soleus Capital Management, L.P. | 2,927,895 | -1,101,424 |
| Clearbridge Investments, LLC | 2,650,192 | -560,738 |
| Congress Asset Management Co | 2,600,123 | +432,042 |
| Two Sigma Investments, LP | 2,468,971 | +926,659 |
| Goldman Sachs Group Inc | 2,314,279 | +26,591 |
| Pictet Asset Management Holding SA | 1,785,951 | +38,578 |
| Jane Street Group, LLC | 1,752,646 | -289,023 |
| Nuveen, LLC | 1,625,876 | +178,798 |
| Morgan Stanley | 1,601,714 | +193,544 |
| Hood River Capital Management LLC | 1,600,510 | +31,339 |
| Northern Trust Corp | 1,537,059 | +94,480 |
| Charles Schwab Investment Management Inc | 1,313,103 | +18,048 |
| Bank of America Corp | 1,309,788 | -151,514 |
| Dimensional Fund Advisors LP | 1,210,578 | +125,723 |
Insiders
4 insiders reported holding 10,968,653 shares in total, about $695.2M at the last price.
| Holder | Shares |
|---|---|
| Weiss Michael SCEO, Director | 9,778,086 |
| Power Sean ACFO | 798,111 |
| Echelard YannDirector | 223,816 |
| Charney Laurence NDirector | 168,640 |
Questions about TGTX
What does TG Therapeutics, Inc. do?
TG Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as TGTX. Its shares trade on NASDAQ under the ticker TGTX.
What is TG Therapeutics, Inc.'s net worth?
TG Therapeutics, Inc. has a market value (market cap) of $9.7B at the latest share price, and shareholders' equity of $572.1M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is TG Therapeutics, Inc. profitable?
Yes. Over the twelve months to September 30, 2026 it reported net income of $106.1M on revenue of $897.8M, a net margin of 11.8%.
How much revenue does TG Therapeutics, Inc. make?
Over the twelve months to September 30, 2026 TG Therapeutics, Inc. reported revenue of $897.8M. That is 68.8% more than a year earlier.
When did TG Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is TG Therapeutics, Inc.'s next earnings report?
TG Therapeutics, Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TGTX with
Follow TGTX
Get an email when TG Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values TG Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.